Medicare Part B Payment Boost For Biosimilars A Positive Step But ‘More Must Be Done’
Executive Summary
The policy is welcomed by biosimilar stakeholders, but amounts to a relatively small increase. To qualify for the revised payment, a biosimilar must have an average sales price that is less than its reference drug’s ASP and not all do.
You may also be interested in...
Shared Savings Legislation Could Increase Medicare Biosimilar Access
Congressman Richard Hudson has introduced US legislation calling for a three-year ‘demonstration project’ into a shared savings payment scheme for biosimilar medicines provided through Medicare Part B.
Medicare Drug Payment Demonstration May Advance In 2023 Under Executive Order
Demonstration would ‘build on’ Medicare price controls established by the Inflation Reduction Act, White House says.
HHS Price Negotiations Could Be Delayed When Biologics Have Biosimilars Pending Under Bill
Latest iteration of drug pricing legislation from Senate Democrats would also firm up the number of drugs HHS must choose for price negotiation each year and no longer treats insulin as a separate class for purposes of negotiation.